iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) Stock Holdings Lowered by Neumann Capital Management LLC

Neumann Capital Management LLC lowered its position in shares of iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) by 2.7% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 3,658 shares of the financial services provider’s stock after selling 100 shares during the period. Neumann Capital Management LLC’s holdings in iShares Nasdaq Biotechnology ETF were worth $399,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently added to or reduced their stakes in the company. Ellis Investment Partners LLC grew its position in shares of iShares Nasdaq Biotechnology ETF by 10,590.0% during the first quarter. Ellis Investment Partners LLC now owns 1,761,815 shares of the financial services provider’s stock worth $1,761,000 after acquiring an additional 1,745,334 shares during the last quarter. Commerce Bank lifted its holdings in iShares Nasdaq Biotechnology ETF by 1.5% in the first quarter. Commerce Bank now owns 710,753 shares of the financial services provider’s stock worth $79,462,000 after purchasing an additional 10,414 shares during the period. Joseph P. Lucia & Associates LLC acquired a new stake in iShares Nasdaq Biotechnology ETF in the first quarter worth about $2,049,000. Crestwood Advisors Group LLC lifted its holdings in iShares Nasdaq Biotechnology ETF by 5.0% in the first quarter. Crestwood Advisors Group LLC now owns 217,133 shares of the financial services provider’s stock worth $24,275,000 after purchasing an additional 10,390 shares during the period. Finally, Commonwealth Equity Services LLC lifted its holdings in iShares Nasdaq Biotechnology ETF by 1.0% in the first quarter. Commonwealth Equity Services LLC now owns 205,014 shares of the financial services provider’s stock worth $22,920,000 after purchasing an additional 1,936 shares during the period. Institutional investors and hedge funds own 73.00% of the company’s stock.

IBB stock traded down $2.90 during trading on Monday, hitting $102.17. The company had a trading volume of 239,114 shares, compared to its average volume of 2,479,419. The firm has a 50 day moving average price of $106.83. iShares Nasdaq Biotechnology ETF has a fifty-two week low of $89.01 and a fifty-two week high of $122.97.

iShares Nasdaq Biotechnology ETF Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.

Recommended Story: Put Option

Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares Nasdaq Biotechnology ETF (NASDAQ:IBB).

Institutional Ownership by Quarter for iShares Nasdaq Biotechnology ETF (NASDAQ:IBB)

Receive News & Ratings for iShares Nasdaq Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Nasdaq Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.